Cipla's Financial Triumph in Q4

Mumbai-based pharmaceutical giant Cipla has announced an impressive 30% year-on-year increase in net profit, reaching Rs 1,222 crore for the quarter ending March 31. The company's revenue also saw a healthy growth of 9%, totaling Rs 6,730 crore compared to the same period last year.

Annual Performance Highlights

For the fiscal year 2025, Cipla's revenue climbed 8% to Rs 27,548 crore, showcasing the company's robust growth trajectory and operational efficiencies.

Leadership Insights

Umang Vohra, MD and Global CEO of Cipla, shared his optimism regarding the company's performance and future prospects. "We continue to make considerable progress across our focused markets," Vohra stated, highlighting the company's strategic focus and operational achievements.

Market Dynamics and Future Outlook

Addressing recent US policies and their potential impact, Vohra noted, "We don’t see any material impact of tariffs on generics as of now." He further elaborated on the company's strategic priorities, including growing key markets and investing in future pipelines.